NCT01539993已完成不适用
Prospective Analysis of Liver Cancer Treatment and Interventions
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 400
- 试验地点
- 1
- 主要终点
- Assess efficacy of percutaneous and transarterial treatments for liver cancer.
研究概览
简要总结
This study is designed for patients diagnosed with Liver cancer to collect information about the relationship between types of liver cancer, methods of treatment and outcomes over time.
研究设计
- 研究类型
- Observational
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients diagnosed with Hepatocellular carcinoma and referred for percutaneous liver treatment.
排除标准
- •Severe liver disfunction
- •Active uncontrolled infection
- •Significant underlying medical of physical illness
结局指标
主要结局
Assess efficacy of percutaneous and transarterial treatments for liver cancer.
时间窗: 1 month
QOL questionnaire will be collected during follow up visit.
次要结局
- long term follow up(3 months, 6 months 1year)
研究者
Hyun Kevin Kim
MD FSIR, Director of Interventional Radiology and Image-Guided Medicine.
Emory University
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
Prospective Validation of Liver Cancer Risk Computation (LIRIC) ModelsPredictive Cancer ModelNCT06140823Beth Israel Deaconess Medical Center6,000,000
招募中
不适用
Liver Cancer and Immunotherapy in the Liquid Biopsy EraBCLC Stage B Hepatocellular CarcinomaHepatocellular CarcinomaBCLC Stage C Hepatocellular CarcinomaImmune Checkpoint InhibitorLiquid BiopsyNCT05810402University Hospital, Montpellier60
招募中
不适用
Evaluation of Patients With Liver DiseaseHepatitis DHepatitis BLiver DiseaseHepatitis CNCT00001971National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)8,050
进行中（未招募）
不适用
Surveys, Blood Testing, and Fibroscan in Screening for Liver Fibrosis and Liver CirrhosisLiver and Intrahepatic Bile Duct CarcinomaNCT04785534M.D. Anderson Cancer Center1,000
招募中
不适用
Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related TherapiesHematopoietic and Lymphoid Cell NeoplasmMalignant Solid NeoplasmNCT05108519M.D. Anderson Cancer Center170